Applied DNA Sciences Stock Scheduled to Reverse Split on Thursday, April 25th (NASDAQ:APDN)

Applied DNA Sciences, Inc. (NASDAQ:APDN) shares are scheduled to reverse split before the market opens on Thursday, April 25th. The 1-20 reverse split was announced on Thursday, April 25th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 25th.

Applied DNA Sciences Price Performance

APDN traded down $0.04 during trading on Tuesday, reaching $0.29. The company had a trading volume of 811,420 shares, compared to its average volume of 116,854. The business’s fifty day moving average price is $0.49 and its 200 day moving average price is $0.67. The company has a market cap of $4.92 million, a P/E ratio of -0.54 and a beta of 0.07. Applied DNA Sciences has a 12 month low of $0.28 and a 12 month high of $1.86.

Applied DNA Sciences (NASDAQ:APDN) last announced its quarterly earnings data on Thursday, February 8th. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.22. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $0.70 million. Applied DNA Sciences had a negative net margin of 80.14% and a negative return on equity of 159.93%. As a group, sell-side analysts predict that Applied DNA Sciences will post -0.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on APDN. HC Wainwright dropped their price target on shares of Applied DNA Sciences from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Friday, February 9th. StockNews.com began coverage on shares of Applied DNA Sciences in a research report on Sunday. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC acquired a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 22.22% of the company’s stock.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.